Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021

Rhea-AI Summary

Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company (Nasdaq: OCUP), announced that CEO Mina Sooch will present a corporate overview at the 2021 BIO CEO & Investor Conference from February 16-18, 2021. The company will also participate in a panel discussion on February 19, 2021, focusing on key events in ophthalmology. Attendees can access a pre-recorded presentation via the conference portal until March 14. Ocuphire's pipeline includes Nyxol, a lead product entering Phase 3 trials for night vision disturbances, and APX3330, an oral tablet for retinal diseases.

FARMINGTON HILLS, Mich., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, Chief Executive Officer will present a corporate overview at the 2021 BIO CEO & Investor Conference and participate in select one-on-one investor meetings from February 16 to 18, 2021. Ocuphire’s management will also participate in Cantor Fitzgerald’s Eyeing Key Events and Programs in the Ophthalmology Space in 2021 Panel on February 19, 2021 at 10:30am EST.

Beginning February 16^th, a pre-recorded presentation by company management will be available for on-demand viewing by registered attendees anytime through March 14th by accessing the BIO CEO Conference portal. For more information about the BIO CEO & Investor Conference, please refer to the conference website at https://www.bio.org/events/bio-ceo-investor-digital-conference

To register in advance for Cantor Fitzgerald’s Eyeing Key Events and Programs in the Ophthalmology Space in 2021 Panel on February 19, 2021, sign up here.

About Ocuphire Pharma

Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol^® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 7 Phase 1 and 2 trials. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME), and has been studied in 11 Phase 1 and 2 trials. Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s completed Phase 2 clinical trials and ongoing Phase 3 registration trials (NCT04620213 and NCT04638660) and soon to recruit Phase 2 trials (NCT04675151 and NCT04692688). For more information, please visit www.ocuphire.com.

Ocuphire Contacts

Mina Sooch, President & CEO 
Ocuphire Pharma, Inc. 
ir@ocuphire.com
www.ocuphire.com 

Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com

FAQ

When is Ocuphire Pharma's presentation at the BIO CEO & Investor Conference?

Ocuphire Pharma's presentation is scheduled for February 16-18, 2021.

What product is Ocuphire focusing on for night vision disturbances?

Ocuphire is focusing on Nyxol, which is entering Phase 3 clinical development for night vision disturbances.

What is the second product candidate in Ocuphire's pipeline?

The second product candidate is APX3330, designed for retinal diseases such as diabetic retinopathy.

When will the Cantor Fitzgerald panel discussion take place?

The Cantor Fitzgerald panel discussion will occur on February 19, 2021, at 10:30 am EST.

How can I access Ocuphire's pre-recorded presentation?

The pre-recorded presentation will be available on-demand for registered attendees from February 16 through March 14, 2021.